The Role of Fatty Acid-Binding Protein 4 in Pregnancy Complications and Fetal Health
- 1Department of Obstetrics and Perinatology, Medical University of Lublin, ul. Jaczewskiego 8, 20-954 Lublin, Poland
- 2Medical University of Lublin, Al. Racławickie 1, 20-059 Lublin, Poland
Abstract
Fatty acid-binding protein 4 (FABP4) is an adipokine involved in regulating lipid metabolism, glucose homeostasis, and inflammatory processes. Altered circulating FABP4 concentrations have been associated with insulin resistance, adipose tissue dysfunction, and endothelial abnormalities. Growing evidence suggests that FABP4 dysregulation may contribute to impaired maternal metabolic and vascular adaptation during pregnancy, although the underlying mechanisms remain incompletely understood. FABP4 has been implicated in the pathophysiology of several pregnancy-related conditions, including maternal obesity, gestational diabetes mellitus, hypertensive disorders of pregnancy, preeclampsia, and recurrent pregnancy loss. Circulating FABP4 has also emerged as a potential biomarker for the early identification of women at increased risk of pregnancy-related metabolic and vascular complications, potentially improving risk assessment and providing earlier preventive or therapeutic interventions. This review summarizes current evidence on the role of FABP4 during pregnancy and its potential involvement in the pathophysiology of pregnancy-related complications, with particular emphasis on its biological functions, diagnostic and prognostic potential, and emerging therapeutic implications. Further mechanistic and prospective clinical studies are needed to determine whether FABP4 is a clinically useful biomarker and to clarify its potential as a therapeutic target in the management of pregnancy-related complications.
Related
- Nonlinear Dose–Response Association Between Exercise Intensity and Urinary Liver-Type Fatty Acid-Binding Protein in Young Men: A Piecewise Threshold Analysis
- Fatty Acid-Binding Protein 3 (FABP3)-Mediated Abdominal Fat Deposition in Broilers via the PPAR Signaling Pathway
- Structural Determinants Underlying the Interplay Between Fatty Acid Binding and S-Nitrosylation of Human Serum Albumin
- A small molecule inhibitor of human ARV1 sterol-binding protein blocks lipid binding
- A Hepatitis B virus pregenomic RNA based minigene transcript utilizes polypyrimidine tract binding protein regulated NXF1-NXT1 nuclear export pathway
BibTeX
@article{mierzynski2026role,
title = {{The Role of Fatty Acid-Binding Protein 4 in Pregnancy Complications and Fetal Health}},
author = {Radzisław Mierzyński and Elżbieta Poniedziałek-Czajkowska and Kamila Świda and Katarzyna Mierzyńska},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms27219860},
url = {https://www.mdpi.com/1422-0067/27/21/9860},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The Role of Fatty Acid-Binding Protein 4 in Pregnancy Complications and Fetal Health
AU - Radzisław Mierzyński
AU - Elżbieta Poniedziałek-Czajkowska
AU - Kamila Świda
AU - Katarzyna Mierzyńska
PY - 2026
DA - 2026/11/03
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219860
UR - https://www.mdpi.com/1422-0067/27/21/9860
AB - Fatty acid-binding protein 4 (FABP4) is an adipokine involved in regulating lipid metabolism, glucose homeostasis, and inflammatory processes. Altered circulating FABP4 concentrations have been associated with insulin resistance, adipose tissue dysfunction, and endothelial abnormalities. Growing evidence suggests that FABP4 dysregulation may contribute to impaired maternal metabolic and vascular adaptation during pregnancy, although the underlying mechanisms remain incompletely understood. FABP4 has been implicated in the pathophysiology of several pregnancy-related conditions, including maternal obesity, gestational diabetes mellitus, hypertensive disorders of pregnancy, preeclampsia, and recurrent pregnancy loss. Circulating FABP4 has also emerged as a potential biomarker for the early identification of women at increased risk of pregnancy-related metabolic and vascular complications, potentially improving risk assessment and providing earlier preventive or therapeutic interventions. This review summarizes current evidence on the role of FABP4 during pregnancy and its potential involvement in the pathophysiology of pregnancy-related complications, with particular emphasis on its biological functions, diagnostic and prognostic potential, and emerging therapeutic implications. Further mechanistic and prospective clinical studies are needed to determine whether FABP4 is a clinically useful biomarker and to clarify its potential as a therapeutic target in the management of pregnancy-related complications.
SN - 1422-0067
ER -